
Alexion Pharmaceuticals ( ALXN +5.2% ) pops after Standard & Poors announces it will replace Motorola Mobility ( MMI ) in the S&P 500 index after the close of trading on Thursday, May 24. Post your comment!
By ZetaKap : Interested in gaining exposure to biotechnology companies? Do you prefer stocks that are projected to grow over the long term? Do you prefer investing in stocks that analysts have weighed in on? If so, here's a list you might be interested in. EPS growth (earnings per share growth) ...
By Rod Raynovich : Why is the biotechnology sector still strong? Despite all the gloom and doom in the markets over the past 60 days the biotechnology sector has barely flinched and is currently at YTD highs. Bellwether ETFs IBB (126) and XBI ($82.85) are up over 20% YTD after a brief correction in
By ZetaKap : Interested in biotechnology companies? Do you value companies holding large amounts of cash? Do you prefer stocks with high projected earnings over the next year? If so, you'll probably like this list. The Current ratio is a liquidity ratio used to determine a company's financial ...
Alexion Pharmaceuticals Inc. ( ALXN ) Deutsche Bank Securities, Inc. 37th Annual Health Care Conference May 7, 2012 11:20 AM ET Executives Vikas Sinha – CFO Analysts
By Andrew McDonald : By Andrew McDonald, Ph.D. and Ning Yang, Ph.D. On April 2, 2012, Dr. Mitesh J. Borad, the principal investigator of Phase IIb clinical trial for Threshold Pharmaceutical's ( THLD ) leading drug candidate TH-302 in pancreatic cancer indication, presented the detailed results of
By ValueMax : The past week has seen various conflicting reports for QuestCor Pharmaceuticals ( QCOR ) One article reports that Questcor stock could dive due to its weak pipeline. The company has no new drugs in development, and is focusing on therapeutic areas alone. Even with this in mind, ...
Alexion ( ALXN +1.8% ) bounces back today after slipping despite a strong earnings report yesterday. Jefferies ups its price target from
Alexion ALXN reported very strong first-quarter results that illustrated the value of its highly profitable rare-disease drug Soliris. Although
Alexion Pharmaceuticals , Inc. ( ALXN ) Q1 2012 Results Earnings Call April 24, 2012 10:00 AM ..... ladies and gentlemen. And welcome to the First Quarter 2012 Alexion Pharmaceuticals ’ Earnings Conference Call. My name is [Alisha], and